Telemonitoring for high-risk pregnant women in Pakistan
Official title: Feasibility of Implementing a Mobile Phone-based Telemonitoring Program to Support Pregnant Women at High-risk for Preeclampsia in Karachi, Pakistan
Run by University Health Network, Toronto · NCT05662696 · Data updated 2026-11-12
A mobile phone app called Raabta will let pregnant women at high risk for preeclampsia in Karachi, Pakistan, regularly track blood pressure and share data with clinicians to see if this helps catch problems earlier.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University Health Network, Toronto Academic / other |
| Locations | 1 site (Karachi, Sindh) |
| Status | Recruiting |
| Started | August 4, 2024 |
| Main results expected | March 1, 2027 |
| Study ends | March 31, 2027 |
| Registry record updated | June 1, 2026 |
| Trial ID | NCT05662696 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Pregnant women in the first or second trimester who are high-risk for preeclampsia and can read/understand Urdu, and who have a caregiver willing to participate in interviews.
✕Probably not a fit
Principle investigators will determine feasibility; some participants may not experience a clear clinical benefit during the study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This interventional study will test a mobile telemonitoring program for pregnant women at high risk of preeclampsia in Karachi. The Raabta app enables daily blood pressure measurements and data transmission to healthcare providers between antenatal visits. A mixed-methods approach will enroll about 50 participants to assess feasibility, including how well the technology works, potential barriers, and user experiences. The study builds on prior LMIC telemonitoring work but focuses on early risk detection outside routine community health worker visits. Data will be hosted by the Centre for Digital Therapeutics at UHN in Toronto, with local clinical sites overseeing implementation.
Why it matters
Potential benefit: If successful, Raabta could improve early detection and timely management of preeclampsia in high-risk pregnancies.
How similar studies have gone: Previous LMIC telemonitoring efforts showed promise but often relied on in-person visits by community health workers; this study tests a direct patient-facing app in a hospital-based LMIC setting.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Pregnant women at high-risk for preeclampsia (HRPE) who are either in their first or second trimester of pregnancy. The definition of HRPE will follow that of the NICE guidelines that define pregnant women at HRPE as those who have one high-risk factor or more than one moderate risk factor for preeclampsia. * Participants who can speak and read (at least at a rudimentary level with help from a caregiver) the Urdu language for ease of communication with the research team and to be able to use the telemonitoring system. * Partners (almost always male husbands in the Pakistani culture) and/or other caregivers (e.g., mother and mother-in-law) of pregnant women \[for post-study interviews\] * Clinicians and nurses involved in the implementation of the telemonitoring program \[for post-study interviews\] Exclusion Criteria: * Pregnant women at high-risk for preeclampsia who are admitted to hospital for the management of their preeclampsia condition
Where it's running
-
Jinnah Postgraduate Medical Centre
Karachi, Sindh, Pakistan Recruiting
Study contacts
- Principal investigator: Emily Seto, PhD — University of Toronto
- Study coordinator: Emily Seto, PhD
- Email: emily.seto@utoronto.ca
- Phone: 416-669-9295
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Predicting Adverse Pregnancy Outcomes in Uganda through Partnerships and Innovation
This study tests whether everyday health data, ultrasound, and blood samples from first-time pregnant women in Uganda can help predict problems like preeclampsia, fetal growth restriction, and preterm birth.
-
Internal jugular vein collapsibility to gauge volume status in preeclampsia vs. normal pregnancy
This study tests whether ultrasound of the internal jugular vein can show differences in fluid status between preeclamptic pregnant people and those with normal blood pressure during planned cesarean delivery.
-
Higher vs lower daily aspirin in high-risk pregnant people
This study tests whether taking 150 mg of aspirin daily is more effective than 75 mg daily in preventing preeclampsia among pregnant people at high risk.
-
Community health worker support to lower blood pressure after pregnancy with high blood pressure
Postpartum patients with high blood pressure after pregnancy will try a program where a trained community health worker helps them monitor blood pressure and manage care for 6 months to see if it lowers blood pressure compared with usual care.
-
Role of Progesterone Membrane Receptors in Preeclampsia
This study looks at whether the levels of progesterone membrane receptors in the placenta differ between women with preeclampsia and healthy pregnant women to understand the condition better.
-
Endothelial Biomarkers in Pregnancy: Endothelial Extracellular Vesicles and Hypertensive Disorders
This study tests whether endothelial extracellular vesicles in the blood differ between normotensive pregnant women and those with hypertensive disorders of pregnancy.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.